Raymond James raised the price target for the ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock from “an Outperform” to “a Mkt perform”. The rating was released on August 10, 2021. We previously noted in another research note published on March 12, 2021 by Jefferies that downgraded the stock from a Buy to a Hold with a price target of $5 for ZIOP stock. The stock was initiated by Jefferies, who disclosed in a research note on June 19, 2020, to Buy and set the price objective to $7. In their research brief published March 04, 2020, Cantor Fitzgerald analysts initiated the ZIOPHARM Oncology Inc. stock to Overweight with a price target of $6.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The latest trade, Performances and Moving Averages give us the following Picture
The share price of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) dipped -6.78% to close Friday’s market session at $1.65, lower as compared to yesterday’s close. The stock price fluctuated between $1.60 and $1.79 throughout the trading session with the volume trading being 1809341 shares, which represented a significant variation when compared to the three months average volume of 1.93 million shares. The firm’s stock price fluctuated -6.25% within the last five trades and -28.57% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -59.46% in the last 6 months and -45.00% was subtracted to its value over the previous 3 months. ZIOP stock is trading at a margin of -6.46%, -23.91% and -47.69% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, ZIOP deals in the Healthcare domain. The stock is trading -72.27 percent below its 52-week high and 30.95 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -57.4. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does ZIOPHARM Oncology Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $381.50 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 4.02, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.40 percent of ZIOPHARM Oncology Inc. shares are owned by insiders, and 57.50 percent are held by financial institutions. Hagen Heidi, the Director at ZIOPHARM Oncology Inc. (ZIOP) has bought 23,770 shares of firm on Sep 02 at a price of $1.76 against the total amount of $41835.0. In another inside trade, Postma Robert W, Director of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) bought 54,492 shares of the firm on Sep 02 for a total worth of $94271.0 at a price of $1.73. An inside trade which took place on Sep 02, Director of ZIOPHARM Oncology Inc. Postma Robert W bought 20,508 shares of firm against total price of $35479.0 at the cost of $1.73 per share.